Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales.
It is a $161B healthcare company. Revenue shrank 0.2% over the last year, it keeps 7¢ of every dollar of sales as profit, and its net debt equals ~4.7 years of free cash flow. It trades at 37.2× earnings — near the highest of its own history.
- Website
- pfizer.com
- Location
- New York, NY
- Employees
- 75 000
- Sector
- Healthcare
- Founded
- 1849
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Growth and Profitability lag behind.
Valuation52
- P/E vs own history97th pct · 0/25
- FCF yield6.8% · 20/25
- P/S2.5x · 20/25
- EV/EBITDA24.4x · 12/25
Growth25
- Revenue CAGR-6.3% · 0/25
- Net income CAGR-22.9% · 0/25
- EPS CAGR ~5Y-4.4% · 0/25
- Fwd implied growth288.4% · 25/25
Profitability28
- ROIC5.6% · 5/25
- ROE4.9% · 5/25
- Net margin6.8% · 13/25
- Operating margin6.8% · 5/25
Health52
- Altman Z1.96 · 10/25
- Current ratio1.27 · 12/25
- Interest coverage5.0x · 18/25
- Net cash / debtD/A 25% · 12/25
Quality72
- Piotroski F4/9 · 10/25
- Beneish M-2.68 · 25/25
- FCF conversion253% · 25/25
- Margin stabilityσ 8.3% · 12/25
Moat68
- ROIC >12% years3/10 yrs · 6/25
- Median gross margin75.5% · 25/25
- FCF-positive years10/10 yrs · 25/25
- Worst-year net marginworst 3.6% · 12/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- Q3 2026Insiders3 open-market insider purchases~115K shares bought by insiders
- 2024ProductInitially the partnership focused on automating data review processes with the Smart Data Quality (SDQ) platform —…
- FY2022FinancialRevenue crossed $100B$100B for the year
- FY2022FinancialBest year on record$31.4B net income
- Dec 11, 2020ProductComirnatywith BioNTech — first authorized mRNA COVID vaccine
- FY2016FinancialProfitable every year on record10 consecutive profitable years in our data
- FY2016FinancialRevenue already above $50B$52.8B in first reported year
- FY2016FinancialPositive free cash flow every year since10-year streak
- 2016AcquisitionPfizer acquired AstraZeneca's small-molecule antibiotics business for $1.575 billion
- Nov 23, 2015AcquisitionPfizer and Allergan announced a planned $160 billion merger, in the largest pharmaceutical…
- 2014AcquisitionThe company acquired Innopharma for $225 million, plus up to $135 million in milestone payments,…
- 2011AcquisitionPfizer acquired King Pharmaceuticals for $3.6 billion in cash
- 2000AcquisitionPfizer acquired Warner-Lambert outright for $116 billion
- 1997ProductLipitor eravia the Warner-Lambert merger — the best-selling drug ever
- 1986AcquisitionPfizer acquired the worldwide rights to Zithromax (azithromycin), a macrolide antibiotic that is…
- 1980ProductPfizer launched Feldene (piroxicam), a prescription anti-inflammatory medication that became Pfizer's first…
- Jun 22, 1942IPOIPOwent public as wartime penicillin production scaled up
- 1849FoundedFounded in BrooklynCharles Pfizer and Charles Erhart, German immigrants
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (74.7%)
- Strong cash conversion — FCF is 17.2% of revenue
- Interest covered 5.0× by operating earnings
Watch-outs
- Revenue shrinking 0.2% year over year
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago-0.2% YoY
- Profitable — makes more than it spends$4.33B TTM
- Profit growing — earnings are higher than last year-37.1% YoY
- Generates cash — cash left after running and investing$11.0B TTM
- Debt under control — could handle its obligations~4.7y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$161B market cap
- Not printing shares — share count not ballooning — you keep your slice+1.4% shares over ~5y
- Proven track record — years of profitability behind it10/10 profitable years
- Financially stable — balance sheet not near distressAltman Z 2.0 — grey
- Pays a dividend — returns cash to shareholdersyield 6.07%
- Valuation not extreme — price not wildly above earningsP/E 37.2
Peer comparisonPfizer Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| PFE this company | $161.1B | 37.2 | -0.2% | 6.8% | Mixed |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: PFE vs LLY · PFE vs JNJ · PFE vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/PFE
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of PFE on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $28.27 · market cap $161B.